Michael J. Fox Foundation Archives
Vanderbilt licenses compound to Nashville’s Appello to advance Parkinson’s therapies
Jul. 12, 2018—Vanderbilt University has signed a licensing agreement with Nashville-based start-up Appello Pharmaceuticals, Inc. to advance novel compounds developed by researchers in the Vanderbilt Center for Neuroscience Drug Discovery (VCNDD) for the treatment of Parkinson’s disease.
Amish aid study of Parkinson genetics
Nov. 11, 2013—Amish populations are valuable for genetic research because of their isolation, shared ancestry and homogeneous lifestyles.
VU, Bristol-Myers to collaborate on Parkinson’s therapies
Sep. 21, 2012—Vanderbilt University and Bristol-Myers Squibb have signed a collaboration agreement for the discovery, development and commercialization of novel therapies acting on the mGluR4 glutamate receptor, known as positive allosteric modulators, or PAMs, for the treatment of Parkinson’s disease.
Neuroscience drug discovery center opens at Vanderbilt
Mar. 11, 2011—Vanderbilt University Medical Center has established a new Center for Neuroscience Drug Discovery to accelerate research that may lead to new treatments for Parkinson's disease, schizophrenia and other disorders of the brain.
